Shreis Scalene Therapeutics (SSTx), a Md.-based medical device company, will fast-track the manufacture and distribution of the CE-marked (EU-Class 1) Scalene Hypercharge Corona Canon (SHYCOCAN) under U.S. FDA “Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency.”

“This innovative technology is intended to ‘physically attenuate’ the homing mechanism on the virus and prevent infectivity,” says SHYCOCAN device inventor, Rajah Vijay Kumar, OMS, DSc, chairman and chief scientific officer of the Organization de Scalene and Scalene Cybernetics Ltd. in Bengaluru, India, and long-standing technology partner of the Shreis Scalene Group of US Companies.

The device is designed to release a very high concentration of environmentally safe electrons using proprietary Photon-Mediated Electron Emitters (PMEEs) made with a superalloy developed by Scalene, applying well-known principles of physics, to emit and excite photons with the required kinetic energy. As the photons bombard bulk surfaces and suspended particles in confined environments, the emanated electron cloud actively ‘disarms’ air and surface transmission of the Corona family of viruses. The SHYCOCAN does not use any chemicals nor does it produce ozone, or ionize the air to produce reactive oxygen species, oxides of nitrogen or other harmful compounds. The device can be safely deployed in all environments inhabited by people, be it very large or small enclosed spaces.

The attachment of the SARS-CoV-2 to the host cell receptor is mediated by the spike protein (S-protein). The hypercharge electrons flooding exposed areas are ‘attracted’ to the virus’ S-protein, thereby disabling infectivity. Data from lab studies have indicated significant viricidal impact with a 3.435 Log10 reduction demonstrated in an EPA-approved phylogenetic surrogate, resulting in 99.9% reduction in infectivity. There is also emerging evidence for the significant disabling of the Influenza B viral capsid (a strain within the coronavirus family), by the SHYCOCAN.

“An important feature of this technology is that only the Corona family of viruses is targeted, while bacteria, fungi, or other eco-friendly micro-organisms are not, allowing for 24/7, safe deployment,” clarifies Kumar.  

Initiatives surrounding the research and development on the device prototype began in April 2019, to stem the decline in work force productivity due to the common cold and seasonal Influenza in Scalene’s facilities. Over the last 6 months, Kumar and his team have worked tirelessly and successfully completed extensive EU-CE – mandated safety testing undertaken by the Underwriters Laboratories (UL). Scalene has since obtained the CE Mark with Class I designation, enabling the expedited manufacture, distribution, and sales in all CE-compliant countries/markets, including India.

“The phased deployment of the SHYCOCAN is being discussed with a top tier global manufacturing company for mass production and distribution,” says Rayol John Augustus PhD, co-founder and COO of SSTx and the founder president of the Shreis Group of medical device companies. “Physically attenuating and disabling active viral transmission with a design-registered device using patent-protected PMEEs, the SHYCOCAN will help create ‘safer zones’ in homes, healthcare facilities, [and other] environments, to fill unmet needs. The low-cost, plug and play device, that can be safely installed in a large variety of indoor settings, makes it a very practical and complementary solution—along with the use of personal protective equipment (PPE), where necessary—to reduce burdens of indefinite social distancing.”

Featured image: SHYCOCAN Photon-Mediated Electron Emitters (PMEEs) (Credit: Shreis Scalene Therapeutics)